HCV-positive donor kidney to HCV-positive recipient transplantation transmission relationship

The HCV-positive donor kidney to HCV-positive recipient transplantation transmission relationship is a clinical and organizational relationship shaped by two competing facts: kidney transplantation can transmit HCV, yet refusing every kidney from an HCV-positive donor can waste organs during a severe shortage. The evidence supports a conditional rather than absolute policy. In carefully selected HCV-positive recipients, particularly those with active HCV RNA in the bloodstream before transplantation, transplantation from an HCV-positive donor has generally produced favorable graft, patient, and liver-related outcomes, while still carrying a real possibility of viral transmission or superinfection.

Definition and Clinical Problem

The relationship begins with a distinction between HCV serology and active infection. Anti-HCV antibodies do not confer immunity and do not establish that a recipient is currently viremic. Consequently, an HCV-positive recipient may still acquire infection from an HCV-positive kidney, especially if the donor carries a different viral genotype. The use of such a kidney therefore does not eliminate transmission; it changes the clinical context in which transmission occurs, from an HCV-negative recipient who should ordinarily be protected from infection to an already infected recipient for whom the principal questions are additional viral exposure, liver injury, graft safety, waiting time, and the comparative risks of remaining on dialysis.

Early transplantation experiences established that HCV can be transmitted through a transplanted kidney. Across reported series involving kidneys from HCV RNA-positive donors, transmission probabilities ranged from 14% to 100%. Clinical consequences were heterogeneous: in one series, half of the recipients who acquired HCV through transplantation developed criteria for chronic liver disease, whereas chronic liver disease was much less frequent in another center's experience. Differences in donor viral load, strain infectivity, the volume of preservation solution, preservation method, and diagnostic testing were proposed as explanations for the wide variation.

Because of this risk, there was broad agreement that kidneys from HCV-positive donors should not be transplanted into HCV-negative recipients, regardless of whether donor HCV RNA was detected. The unresolved question was whether the organs could be used in HCV-positive recipients without creating unacceptable additional harm. The answer became more favorable as center-based experience accumulated, but only after the evidence clarified that HCV-positive status was not synonymous with immunity or guaranteed protection against a new transmission event.

Evidence from the Spanish Pilot Experience

In March 1990, two Spanish kidney-transplant units began a pilot program using kidneys from HCV-positive donors in HCV-positive recipients. The initial short-term results were reassuring. Graft survival and patient survival among HCV-positive recipients were similar whether the donor was HCV-positive or HCV-negative. The proportion of patients developing biochemical evidence consistent with chronic liver disease was also comparable between the groups, with chronic liver disease defined by alanine aminotransferase levels exceeding 2.5 times the upper limit of normal for more than six consecutive months.

The apparent safety of the first comparison did not mean that transmission had been prevented. When donor and recipient samples were later examined with polymerase chain reaction testing, five recipients who had been HCV RNA-negative were found to have received kidneys from donors with positive HCV RNA. Four of those five recipients became HCV RNA-positive after transplantation, and two developed chronic liver disease. The finding exposed the limitation of relying on antibody status or incomplete pretransplant molecular information and prompted a decisive change in policy.

In March 1993, the Spanish groups therefore limited this transplantation strategy to waiting-list patients who had positive HCV RNA before transplantation. This change did not deny the possibility of transmission; it narrowed the recipient population to patients already demonstrably infected and made the risk more explicit. Later single-center experiences using the same general approach reported similar short-term comparisons, with HCV-positive recipients receiving kidneys from HCV-positive donors showing outcomes comparable to those receiving kidneys from HCV-negative donors.

Benefits, Risks, and Conflicting Evidence

One practical benefit was a shorter time on the kidney waiting list. Several center-based series reported that HCV-positive recipients transplanted with kidneys from HCV-positive donors waited significantly less time than comparable candidates who received other organs. For patients who remain exposed to the morbidity and mortality of end-stage renal disease while waiting, this reduction in waiting time could be clinically meaningful. It also offered a use for organs that might otherwise be rejected solely because of donor HCV status.

The center-based evidence was not uniformly matched by registry evidence. Analyses of the United States Renal Data System described lower patient survival after transplantation from HCV-positive rather than HCV-negative donors, regardless of the recipient's HCV serology, with the difference becoming apparent approximately two years after transplantation. One possible intermediate complication was the higher incidence of posttransplant diabetes mellitus among recipients of kidneys from HCV-positive donors. These findings led the authors to recommend caution and complete disclosure to potential recipients rather than unrestricted acceptance of the practice.

The broader clinical setting also complicates the risk calculation. HCV infection is frequently asymptomatic in patients receiving long-term dialysis, and symptoms such as fatigue, cognitive impairment, or depression may overlap with the burdens of dialysis itself. Nevertheless, HCV-positive dialysis patients have worse overall survival in observational evidence: a meta-analysis of 11,589 dialysis patients found an adjusted all-cause mortality risk of 1.34 for those with anti-HCV antibodies, while unadjusted liver-related mortality risk was 5.89. HCV-positive status was also associated with reduced mental quality-of-life scores in a study of 165 dialysis patients, although no association with the physical component score was found. These facts explain why an HCV-positive patient may rationally accept a bounded transplantation risk when the alternative is prolonged dialysis, even though the transplant cannot be described as transmission-free.

Policy, Consent, and Recipient Selection

The resulting recommendation is that kidneys from HCV-positive donors should be offered only to waiting-list candidates with positive HCV RNA and with advance consent to receive such an organ. The requirement for detectable HCV RNA is more precise than antibody positivity alone because it identifies active infection rather than prior exposure or an uncertain serologic state. Advance consent is equally important: the recipient must understand that donor-derived transmission or superinfection remains possible and that the organ is being offered within a deliberate risk–benefit framework.

The strategy must also be distinguished from pretransplant antiviral treatment aimed at achieving a sustained virological response. Eradicating HCV before transplantation may reduce the risk of posttransplant HCV-related glomerular disease and other complications, but it is not compatible with receiving an HCV-positive kidney under a policy restricted to already viremic recipients. Treatment may be prolonged, expensive, poorly tolerated, and unsuccessful in some patients; adverse effects can lead to dose reduction or discontinuation. Patients who decline therapy, fail to respond, or cannot complete it may nevertheless have a more favorable expected course after transplantation than if they remain on dialysis, making an HCV-positive kidney a possible option rather than an automatic exclusion.

The proposed ideal safeguard is matching donor and recipient according to HCV genotype, which could reduce the possibility of superinfection with a different strain. In practice, time constraints and organ-allocation logistics limit how consistently genotype matching can be applied. The recommendation therefore remains an added refinement rather than an absolute prerequisite, while molecular testing and explicit consent form the essential safeguards.

Organ Shortage and Long-Term Significance

The policy exists within a widening imbalance between organ supply and demand. At the end of 2009, approximately 63,000 people were on an organ waiting list in the European Union while about 28,000 transplant procedures were performed during that year. In the United States, nearly 111,000 people were registered on the waiting list in May 2011, with roughly 28,000 transplant procedures performed annually. Against this background, discarding a usable kidney because its donor is HCV-positive has consequences beyond an individual acceptance decision: it can lengthen waiting times and leave patients deteriorating or dying before transplantation.

The paradox is that successful HCV treatment and prevention have reduced the number of actively infected end-stage renal disease patients available to receive these organs. HCV-positive kidneys are consequently becoming surplus organs, while local policies still vary widely and many centers refuse them. One analysis found that donated HCV-positive kidneys were 2.60 times more likely to be discarded than HCV-negative kidneys. The problem is therefore not simply biological risk; it is also a coordination problem involving testing, referral, allocation, consent, and cooperation between centers.

The evidence-based conclusion is conditional reassurance. Center-based studies support the long-term safety of using HCV-positive kidneys in appropriately selected HCV-positive recipients, with favorable graft survival, patient survival, and HCV-related liver outcomes. The approach does not guarantee that transmission will not occur, and registry findings require ongoing caution, especially regarding later complications such as posttransplant diabetes mellitus. Its safety is improved by limiting transplantation to HCV RNA-positive recipients, discussing the risks in advance, and matching viral genotypes when possible. Organizational measures, including preemptive transplantation and broader intercenter cooperation, are presented as necessary if these kidneys are to benefit patients rather than be lost during a period of dramatic organ shortage.